LIVE Price Database Suppliers B2B suppliers Quality & badges Encyclopedia Articles
LONGEVITY TOPICS
NAD+ Precursors Sirtuin Activators Senolytics Autophagy Mitochondrial Hormesis
About PeptideCompare Business Network Contact Policy
Home / Encyclopedia / GLP-1 & Weight / VK2735
MONOGRAPH No. 102
EVIDENCE BASEModerate
TYPE
GLP-1 / GIP dual agonist
MW
Peptide (undisclosed)
CAS
Not assigned
EU STATUS
Investigational · Not approved
WADA
Not listed
MIN PURITY
≥98% HPLC
⚖ GLP-1 & Weight

VK2735 — EU research guide.

VK2735 (Viking Therapeutics) is a dual GLP-1 / GIP receptor agonist in clinical development for obesity, in both subcutaneous and oral formulations. It is investigational and not approved anywhere.

Last reviewed:

What is VK2735?

VK2735 is an investigational dual agonist of the GLP-1 and GIP receptors developed by Viking Therapeutics — the same dual-incretin mechanism class as tirzepatide. It is being developed in two formulations: a subcutaneous injection and an oral tablet, with the goal of covering both the injectable and oral obesity markets with one molecule.

What does the research show?

In a Phase 2 study of the subcutaneous formulation (VENTURE), VK2735 produced mean weight loss of up to ~14.7% over 13 weeks, with the weight-loss curve still declining at the end of dosing (no plateau). The oral tablet's Phase 2 VENTURE-Oral trial (reported August 2025) met its primary endpoint, with up to ~12.2% mean weight loss from baseline at 13 weeks, though a notable dropout rate was discussed by analysts. The subcutaneous programme has advanced into Phase 3 (VANQUISH-1 and VANQUISH-2). As of September 2026 VK2735 is not approved by any regulator.

EU legal status

Not approved in the EU. VK2735 is an investigational pharmaceutical owned by a single developer; it is not a generic research peptide and has no legitimate consumer or research-supply route. Material sold under this name on the gray market cannot be assumed to be authentic VK2735.

⚠ Investigational drug owned by a single developer. Not EMA/FDA-approved. No human use outside authorised clinical trials. Authenticity of gray-market material claiming to be VK2735 cannot be verified.
✓ For approved-mechanism context, PeptideCompare tracks the dual-agonist class (e.g. tirzepatide, retatrutide) from EU research vendors with COA documentation.
EVIDENCE SUMMARY
MODERATE
Weight reduction, subcutaneous form (phase 2, VENTURE) — In a 13-week, randomised, double-blind, placebo-controlled phase 2 trial in 176 adults with obesity or overweight with comorbidities, the sponsor reported mean weight loss of up to 14.7% from baseline versus 1.7% with placebo, with no plateau at week 13. The peer-reviewed report (Obesity, 2026) gives mean losses of 9.2 to 14.6 kg across dose groups versus 1.8 kg with placebo, and at least 5% loss in 130 of 140 treated participants versus 12% on placebo; gastrointestinal events were common but declined with continued treatment.
MODERATE
Weight reduction, oral tablet (phase 2, VENTURE-Oral) — In a 13-week, randomised, double-blind, placebo-controlled phase 2 trial of the once-daily tablet in 280 adults, the sponsor reported mean weight loss of 12.2% at the highest dose versus 1.3% with placebo, with up to 97% of treated participants losing at least 5% (10% on placebo). Nausea (58% vs 48%) and vomiting (26% vs 10%) were the most notable adverse events; these are company results, not a peer-reviewed paper.
MODERATE
Phase 3 status and maintenance data (sponsor reports) — Two 78-week phase 3 trials of the subcutaneous form are fully enrolled (VANQUISH-1, about 4,650 adults with obesity or overweight; VANQUISH-2, about 1,000 adults with type 2 diabetes), with completion expected in 2027, and a phase 3 programme for the tablet is planned to start in the fourth quarter of 2026. A phase 1 maintenance study in about 180 adults (topline, 22 September 2026) reported 16 to 19% weight loss after 21 weeks of induction and retention of up to 97% (every other week) or up to 90% (monthly) of that loss over 12 weeks, versus 61% with placebo.

Molecular information

Molecular weight
Peptide (undisclosed)
CAS number
Not assigned

Pharmacokinetics

Half-life (t½)
≈ 210 h (range 170–250 h)
Source: Viking Therapeutics phase 1 press release, 28 March 2023 (single subcutaneous doses; sponsor-reported range 170 to 250 h, mid-point shown)
Company-reported figure from a press release, not from a peer-reviewed paper.

Potency retained over time

Each line is one storage condition: it starts at 100% and falls as potency is lost. Above the dashed 80% line the material is considered reliable — hover for exact values.

Freezer −20 °C
36+ mo
Stable · >95% potency
Fridge 4 °C
4-6 mo
In use · after recon
Room 20 °C
2-3 wks
Limited · moderate loss
Warm 37 °C+
<1 day
Critical · rapid degradation

⚠ Modelled per compound from molecular structure — chain length, cyclisation, oxidation- and deamidation-prone residues and light sensitivity. Indicative only, not lab-measured per batch.

Dual-agonist compounds across EU suppliers

COA-verified EU vendors · Updated monthly

References

  1. Peer-reviewed report of the 13-week phase 2 trial of the subcutaneous form. It shows weight loss and gastrointestinal tolerability over only 13 weeks and cannot show longer-term efficacy or safety. Bays HE, Toth P, Alkhouri N, Pullman J, Freilich B, Neutel J, Ji S, Stubbe S, Hedges P, Lian B. Weekly subcutaneous VK2735, a GIP/GLP-1 receptor dual agonist, for weight management: phase 2, randomized, 13-week VENTURE study. Obesity (Silver Spring). 2026;34(3):537-549. DOIPubMed 41508550
  2. Sponsor topline release for the same trial: 176 adults, 13 weeks, up to 14.7% mean weight loss versus 1.7% with placebo. A company statement, useful for the headline figures only. Viking Therapeutics. Positive top-line results from the phase 2 VENTURE trial of dual GLP-1/GIP receptor agonist VK2735 in patients with obesity. Press release; 27 February 2024. Source
  3. Sponsor topline release for the oral tablet phase 2 trial (280 adults, 13 weeks) with weight loss and gastrointestinal adverse event rates. A company statement, not peer-reviewed. Viking Therapeutics. Positive top-line results from the phase 2 VENTURE-Oral dosing trial of VK2735 tablet formulation in patients with obesity. Press release; 19 August 2025. Source
  4. Sponsor topline release of the maintenance study (about 180 adults, 21-week induction plus 12-week maintenance). It is an early-phase study with exploratory regimens and a company statement; final data are still to come. Viking Therapeutics. Positive topline results from maintenance study of GLP-1/GIP agonist VK2735 demonstrating the promise of multiple maintenance dosing regimens. Press release; 22 September 2026. Source
  5. Sponsor's second-quarter 2026 report, the source for the current status: both subcutaneous phase 3 trials fully enrolled and the oral phase 3 planned for the fourth quarter of 2026. VK2735 is not approved anywhere, and vials sold by vendors under this name are not the clinical-trial drug. Viking Therapeutics. Second quarter 2026 financial results and corporate update. Press release; 29 July 2026. Source
  6. Sponsor release on the first-in-human phase 1 trial, the only place a half-life figure was found (170 to 250 hours after single subcutaneous doses). Company-reported data from a small early study. Viking Therapeutics. Results from phase 1 clinical trial of dual GLP-1/GIP receptor agonist VK2735. Press release; 28 March 2023. Source

Related guides

GLP-1 & Weight

Tirzepatide
GLP-1 & Weight

Retatrutide
GLP-1 & Weight

Cagrilintide
PeptideCompare AssistantOnline · replies instantly
Hi! I help you quickly find the right page — about legality, COAs, badges or suppliers. No price advice, no dosing.
Try a question
Find a supplier Questions about a peptide? Read our articles Compare prices Is this legal in the EU? How to read a COA What do badges mean? Will customs stop my order? What is BAC water? Talk to a doctor first?
Navigation assistant · no medical advice